SCHEMBL19957017

SCHEMBL19957017

CNc1c(Nc2ccccn2)c(=O)c1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.50
MAPK10 P53779 1/20 0.50
GFER P55789 1/20 0.50
KMT2A Q03164 1/20 0.50
PLK1 P53350 1/20 0.50
ALDH1A1 P00352 3/20 0.45
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
KDM4E B2RXH2 1/20 0.45
MITF O75030 1/20 0.45
LMNA P02545 1/20 0.45
MAPT P10636 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
PKM P14618 1/20 0.43
KDR P35968 2/20 0.42
TSHR P16473 1/20 0.41
ATM Q13315 1/20 0.41
APAF1 O14727 1/20 0.41
TDP2 O95551 1/20 0.41
CDC25B P30305 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7090800 0.79 MEN1 (0.50) MEN1MAPK10GFERKMT2APLK1
SCHEMBL4025790 0.76 GAA (0.57) MEN1MAPK10GFERKMT2APLK1
SCHEMBL12784950 0.75 MAPKAPK2 (0.45) MEN1KMT2APLK1ALDH1A1NPC1
SCHEMBL29520109 0.74
SCHEMBL22421 0.74
SCHEMBL221242 0.73 KMT2A (0.76) MEN1MAPK10GFERKMT2AALDH1A1
SCHEMBL29391624 0.73 KMT2A (0.76) MEN1MAPK10GFERKMT2AALDH1A1
SCHEMBL17123400 0.72 KDR (0.49) MEN1MAPK10GFERKMT2AALDH1A1
Hydrochloric Acid SCHEMBL7383830 0.72
Hydrochloric Acid SCHEMBL5903557 0.72 MEN1 (0.54) MEN1MAPK10GFERKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same Guangdong Raynovent Biotech Co., Ltd. (CN) 2020-05-19 US disclosed
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Guangdong Raynovent Biotech Co., Ltd. (CN) 2019-04-25 US disclosed
EP-3293177-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2018-03-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME ABL1, LCK, ERBB2 MEN1 1450/4885MAPK10 246/4885GFER 3601/4885
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same ABL1, LCK, ERBB2 MEN1 1450/4885MAPK10 246/4885GFER 3601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.